Anna Ulrich

Anna Ulrich

Auto-generated profile, based on publicly available information

Anna Ulrich

Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JSJaco Selle
Jaco Selle
KDKatharina Dinger
Katharina Dinger
VJVanessa Jentgen
Vanessa Jentgen
DZDaniela Zanetti
Daniela Zanetti
JWJohannes Will
Johannes Will
MAMiguel A. Alejandre Alcazar
Miguel A. Alejandre Alcazar
Obesity is a pre-disposing condition for chronic obstructive pulmonary disease, asthma, and pulmonary arterial hypertension. Accumulating evidence suggests that metabolic influences during development can determine chronic lung diseases (CLD). We demonstrate that maternal obesity causes early metabolic disorder in the offspring. Here, interleukin-6 induced bronchial and microvascular smooth muscle cell (SMC) hyperproliferation and increased airway and pulmonary vascular resistance. The key anti-proliferative transcription factor FoxO1 was inactivated via nuclear exclusion. These findings were confirmed using primary SMC treated with interleukin-6 and pharmacological FoxO1 inhibition as well as genetic FoxO1 ablation and constitutive activation. In vivo, we reproduced the structural and functional alterations in offspring of obese dams via the SMC-specific ablation of FoxO1. The reconstitution of FoxO1 using IL-6-deficient mice and pharmacological treatment did not protect against metabolic disorder but prevented SMC hyperproliferation. In human observational studies, childhood obesity was associated with reduced forced expiratory volume in 1 s/forced vital capacity ratio Z-score (used as proxy for lung function) and asthma. We conclude that the interleukin-6-FoxO1 pathway in SMC is a molecular mechanism by which perinatal obesity programs the bronchial and vascular structure and function, thereby driving CLD development. Thus, FoxO1 reconstitution provides a potential therapeutic option for preventing this metabolic programming of CLD.

6 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
AUAnna Ulrich
Anna Ulrich
YWYukyee Wu
Yukyee Wu
HDHarmen Draisma
Harmen Draisma
JWJohn Wharton
John Wharton
ESEmilia M. Swietlik
Emilia M. Swietlik
CRChristopher Rhodes
Christopher Rhodes
Pulmonary arterial hypertension (PAH) is characterised by pulmonary vascular remodelling causing premature death from right heart failure. Established DNA variants influence PAH risk, but susceptibility from epigenetic changes is unknown. We addressed this through epigenome-wide association study (EWAS), testing 865,848 CpG sites for association with PAH in 429 individuals with PAH and 1226 controls. Three loci, at Cathepsin Z (CTSZ, cg04917472), Conserved oligomeric Golgi complex 6 (COG6, cg27396197), and Zinc Finger Protein 678 (ZNF678, cg03144189), reached epigenome-wide significance (p < 10−7) and are hypermethylated in PAH, including in individuals with PAH at 1-year follow-up. Of 16 established PAH genes, only cg10976975 in BMP10 shows hypermethylation in PAH. Hypermethylation at CTSZ is associated with decreased blood cathepsin Z mRNA levels. Knockdown of CTSZ expression in human pulmonary artery endothelial cells increases caspase-3/7 activity (p < 10−4). DNA methylation profiles are altered in PAH, exemplified by the pulmonary endothelial function modifier CTSZ, encoding protease cathepsin Z.

22 October 2020 in Genes
Verified
Journal Article
Open access
PDF file
AUAnna Ulrich
Anna Ulrich
POPablo Otero-Núñez
Pablo Otero-Núñez
JWJohn Wharton
John Wharton
ESEmilia M. Swietlik
Emilia M. Swietlik
SGStefan Gräf
Stefan Gräf
UCUK PAH Cohort Study Consortium
UK PAH Cohort Study Consortium
Expression quantitative trait loci (eQTL) can provide a link between disease susceptibility variants discovered by genetic association studies and biology. To date, eQTL mapping studies have been primarily conducted in healthy individuals from population-based cohorts. Genetic effects have been known to be context-specific and vary with changing environmental stimuli. We conducted a transcriptome- and genome-wide eQTL mapping study in a cohort of patients with idiopathic or heritable pulmonary arterial hypertension (PAH) using RNA sequencing (RNAseq) data from whole blood. We sought confirmation from three published population-based eQTL studies, including the GTEx Project, and followed up potentially novel eQTL not observed in the general population. In total, we identified 2314 eQTL of which 90% were cis-acting and 75% were confirmed by at least one of the published studies. While we observed a higher GWAS trait colocalization rate among confirmed eQTL, colocalisation rate of novel eQTL reported for lung-related phenotypes was twice as high as that of confirmed eQTL. Functional enrichment analysis of genes with novel eQTL in PAH highlighted immune-related processes, a suspected contributor to PAH. These potentially novel eQTL specific to or active in PAH could be useful in understanding genetic risk factors for other diseases that share common mechanisms with PAH.

9 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
VPVincent Pascat
Vincent Pascat
LZLiudmila Zudina
Liudmila Zudina
LMLucas Maurin
Lucas Maurin
AUAnna Ulrich
Anna Ulrich
JMJared G. Maina
Jared G. Maina
IPInga Prokopenko
Inga Prokopenko
Type 2 diabetes and hypertension are common health conditions that often occur together, suggesting shared biological mechanisms. To explore this relationship, we analyse large-scale multiomic data to uncover genetic factors underlying type 2 diabetes and blood pressure comorbidity. We curate 1304 independent single-nucleotide variants associated with type 2 diabetes and blood pressure, grouping them into five clusters related to metabolic syndrome, inverse type 2 diabetes/blood pressure risk, impaired pancreatic beta-cell function, higher adiposity, and vascular dysfunction. Colocalization with tissue-specific gene expression highlights significant enrichment in pathways related to thyroid function and fetal development. Partitioned polygenic scores derived from these clusters improve risk prediction for type 2 diabetes/hypertension comorbidity, identifying individuals with more than twice the usual susceptibility. These results reveal a mechanistically heterogeneous genetic architecture shared between type 2 diabetes and blood pressure, enhancing comorbidity risk prediction. Partitioned polygenic risk scores offer a promising approach for early risk stratification, personalised prevention, and improved management of these interconnected conditions.

6 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
VPVincent Pascat
Vincent Pascat
LZLiudmila Zudina
Liudmila Zudina
LMLucas Maurin
Lucas Maurin
AUAnna Ulrich
Anna Ulrich
JMJared G. Maina
Jared G. Maina
IPInga Prokopenko
Inga Prokopenko
Summary: Type 2 diabetes (T2D) and hypertension are common health conditions that often occur together, suggesting shared biological mechanisms. To explore this relationship, we analysed large-scale multiomic data to uncover genetic factors underlying T2D and blood pressure (BP) comorbidity. We curated 1,304 independent single-nucleotide variants (SNVs) associated with T2D/BP, grouping them into five clusters related to metabolic syndrome, inverse T2D-BP risk, impaired pancreatic beta-cell function, higher adiposity, and vascular dysfunction . Colocalisation with tissue-specific gene expression highlighted significant enrichment in pathways related to thyroid function and fetal development. Partitioned polygenic scores (PGS) derived from these clusters improved risk prediction for T2D-hypertension comorbidity, identifying individuals with more than twice usual susceptibility. These results reveal complex genetic basis of shared T2D and BP mechanistic heterogeneity, enhancing comorbidity risk prediction. Partitioned PGSs offer promising approach for early risk stratification, personalised prevention, and improved management of these interconnected conditions, supporting precision medicine and public health initiatives.